Citations

Clear

371 citation(s) found for "Cho, B".

sFRP3 inhibition improves age‐related cellular changes in BubR1 progeroid mice
Cho, Chang Hoon , Yoo, Ki Hyun , Oliveros, Alfredo , Paulson, Summer G. , Hussaini, Syed Mohammed Qasim, Deursen, Jan M. van , Jang, Mi‐Hyeon , Hussaini, S. M. Qasim , Paulson, Summer

Mayo Clinic

Aging Cell | January 4, 2019 | Volume: 18 | Issue: 2 | Pages: No page available

10.1111/acel.12899 | PMID 30609266 Get It

AbstractWnt signaling is a well‐known molecular pathway in age‐related pathogenesis and therapy of disease. While prior studies have mainly focused on Wnt ligands or Wnt activators, the in vivo functions of naturally secreted Wnt inhibitors are not clear, especially in brain aging. Using BubR1H/H mice as a novel mouse model of accelerated aging, we report that genetic inhibition of sFRP3 restores the reduced body and brain size observed in BubR1H/H mice. Furthermore, sFRP3 inhibition ameliorates hypomyelination in the corpus callosum and rescues neural progenitor proliferation in the hippocampal dentate gyrus of BubR1H/H mice. Taken together, our study identifies sFRP3 as a new molecular factor that cooperates with BubR1 function to regulate brain development, myelination, and hippocampal neurogenesis.
Investigating Perioperative Heart Migration during Robot-Assisted Coronary Artery Bypass Grafting Interventions
Linte, Cristian A. , Cho, Daniel S., Wedlake, Chris, Peters, Terry M. , Kiaii, Bob, Moore, John , Chen, Elvis C. S. , Bainbridge, Daniel , Patel, Rajni V.

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | January 3, 2019 | Volume: 6 | Issue: 5 | Pages: 323-330

10.1177/155698451100600507 Get It

Randomized, open-label, phase II study comparing five-weekly S-1 plus cisplatin (SP) with tri-weekly capecitabine plus cisplatin (XP) in chemotherapy-naïve patients with HER2 negative advanced gastric cancer (AGC): OGSG 1105 HERBIS-4A trial.
Takeno, Atsushi , Makari, Youichi, Matsuyama, Jin , Sugimoto, Naotoshi , Taniguchi, Hirokazu , Nagai, Kenichi, Tamura, Shigeyuki , Nishijima, Junichi, Ueda, Shugo , Kimura, Yutaka , Tamura, Takao , Kobayashi, Kenji , Fujitani, Kazumasa , Sakai, Daisuke , Shimokawa, Toshio , Endo, Shunji , Kawabata, Ryohei , Kawakami, Hisato , Kurokawa, Yukinori , Satoh, Taroh

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: 102-102

10.1200/jco.2018.36.4_suppl.102 Get It

102 Background: This phase II study aimed to investigate the safety and efficacy of XP compared to SP in the first-line treatment of HER2 negative AGC. Methods: Patients were randomly assigned to receive either SP (S-1 at 40–60 mg twice daily for 21 days plus cisplatin at 60 mg/ m2 on day 8, every 5 weeks) or XP (capecitabine 1,000 mg/m2 twice daily for 14 days plus cisplatin 80 mg/m2 on day 1, every 3 weeks). Primary endpoint was response rate (RR), and secondary endpoints were progression-free survival (PFS), overall survival (OS), time to treatment failure (TTF), and adverse events. Results: 84 eligible patients were randomly assigned to receive SP ( N = 41) or XP ( N = 43). No statistical difference was observed in overall RR between the SP and XP groups [51.2% (95% CI, 35.1% to 67.1%) vs. 53.5% (95% CI, 37.7% to 68.8%), P = 1.000]. Despite not significant, however, SP vs. XP showed a trend toward better PFS [median, 5.9 months vs. 4.1 months; hazard ratio (HR), 0.763; 95% CI, 0.462 to 1.259; P = .284] and OS (median, 13.5 months vs. 10.0 months; HR, 0.776; 95% CI, 0.485 to 1.244; P = .290). This trend in the SP vs. XP comparison was more pronounced in TTF (median, 4.5 months vs. 3.1 months; HR, 0.651; 95% CI, 0.421 to 1.006; P = .052). Common grade 3 to 4 hematological toxicities were neutropenia and anemia (SP group, 23% and 23%; XP group, 35% and 28%). Grade 3-4 anorexia and hyponatremia were more frequently seen in the XP group (31% and 16%) compared to the SP group (13% and 5%). Treatment-related deaths occurred in one patient (2.3%) in the XP group. Conclusions: XP failed to demonstrate the superior efficacy over SP. Higher incidence of severe toxicities by XP suggests SP as the standard 1st line chemotherapy for HER2 negative AGC in Japan. Clinical trial information: UMIN000006755.
Postoperative Spine Infection: Diagnosis and Management
Dowdell, James , Brochin, Robert L. , Kim, Jun , Overley, Samuel C. , Oren, Jonathan H., Freedman, Brett A. , Cho, Samuel , Cho, Samuel K. , Cho, Samuel

Mayo Clinic

Global Spine Journal | December 13, 2018 | Volume: 8 | Issue: 4_suppl | Pages: 37S-43S

10.1177/2192568217745512 | PMID 30574436 Get It

Study Design: Review article. Objectives: A review of the literature on postoperative spinal infections, their diagnosis, and management. Methods: A systematic computerized Medline literature search was performed using PubMed, Cochrane Database of Systematic Reviews, and EMBASE. The electronic databases were searched for publication dates from the last 10 years. The searches were performed from Medical Subject Headings (MeSH) used by the National Library of Medicine. Specifically, MeSH terms “spine,” “infections,” “management,” and “diagnosis” were used. Results: Currently, the gold standard for diagnosis of postoperative spine infection is positive deep wound culture. Many of the current radiologic and laboratory tests can assist with the initial diagnosis and monitoring treatment response. Currently erythrocyte sedimentation rate, C-reactive protein, computed tomography scan, and magnetic resonance imaging with and without contrast are used in combination to establish diagnosis. Management of postoperative spine infection involves thorough surgical debridement and targeted antibiotic therapy. Conclusions: Postoperative spine infection is a not uncommon complication following surgery that may have devastating consequences for a patient’s short- and long-term health. A high index of suspicion is needed to make an early diagnosis.
Author response: Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer
Liao, Lili, Langbein, Lauren , Cho, Eun-Ah , Niu, Xiaohua , Jiang, Wei , Zhong, Zhijiu , Jagannathan, Geetha , Dulaimi, Essel, Testa, Joseph R. , Wang, Yuxin , Stark, George R. , Peiper, Stephen, Yang, Haifeng , Liu, Zongzhi Z. , Cai, Weijia , Na, Jie, Cai, Wesley L. , Uzzo, Robert G. , Sun, Jianxin , Xu, Yaomin , Yan, Qin

Mayo Clinic

No container title available | November 12, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.37925.029 Get It

Fast Cyclic Square-Wave Voltammetry To Enhance Neurotransmitter Selectivity and Sensitivity
Park, Cheonho , Shin, Hojin , Kim, Jaekyung , Kang, Yumin , Sim, Jeongeun, Cho, Hyun U., Lee, Han Kyu , Jung, Sung Jun , Bennet, Kevin E. , Heien, Michael L. , Lee, Kendall H. , Kim, In Young , Jang, Dong Pyo , Heien, Michael L , Jang, Dong Pyo , Oh, Yoonbae , Blaha, Charles D.

Mayo Clinic

Analytical Chemistry | October 25, 2018 | Volume: 90 | Issue: 22 | Pages: 13348-13355

10.1021/acs.analchem.8b02920 | PMID 30358389 Get It

Abstract Although fast-scan cyclic voltammetry (FSCV) has been widely used for in vivo neurochemical detection, the sensitivity and selectivity of the technique can be further improved. In this study, we develop fast cyclic square-wave voltammetry (FCSWV) as a novel voltammetric technique that combines large-amplitude cyclic square-wave voltammetry (CSWV) with background subtraction. A large-amplitude, square-shaped potential was applied to induce cycling through multiple redox reactions within a square pulse to increase sensitivity and selectivity when combined with a two-dimensional voltammogram. As a result, FCSWV was significantly more sensitive than FSCV (n = 5 electrodes, two-way ANOVA, p = 0.0002). In addition, FCSWV could differentiate dopamine from other catecholamines (e.g., epinephrine and norepinephrine) and serotonin better than conventional FSCV. With the confirmation that FCSWV did not influence local neuronal activity, despite the large amplitude of the square waveform, it could monitor electrically induced phasic changes in dopamine release in rat striatum before and after injecting nomifensine, a dopamine reuptake inhibitor.
Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer
Liao, Lili, Langbein, Lauren , Cho, Eun-Ah , Niu, Xiaohua , Jiang, Wei , Zhong, Zhijiu , Cai, Wesley L. , Jagannathan, Geetha , Dulaimi, Essel, Testa, Joseph R. , Uzzo, Robert G. , Wang, Yuxin , Stark, George R. , Peiper, Stephen C., Yan, Qin , Yang, Haifeng , Langbein, Lauren , Na, Jie , Xu, Yaomin , Yan, Qin , Yang, Haifeng , Liu, Zongzhi Z. , Cai, Weijia , Na, Jie, Sun, Jianxin

Mayo Clinic

eLife | October 25, 2018 | Volume: 7 | Issue: No issue available | Pages: No page available

10.7554/elife.37925 | PMID 30355451 Get It

Whereas VHL inactivation is a primary event in clear cell renal cell carcinoma (ccRCC), the precise mechanism(s) of how this interacts with the secondary mutations in tumor suppressor genes, including PBRM1 , KDM5C / JARID1C , SETD2 , and/or BAP1 , remains unclear. Gene expression analyses reveal that VHL, PBRM1, or KDM5C share a common regulation of interferon response expression signature. Loss of HIF2α, PBRM1, or KDM5C in VHL-/- cells reduces the expression of interferon stimulated gene factor 3 (ISGF3), a transcription factor that regulates the interferon signature. Moreover, loss of SETD2 or BAP1 also reduces the ISGF3 level. Finally, ISGF3 is strongly tumor-suppressive in a xenograft model as its loss significantly enhances tumor growth. Conversely, reactivation of ISGF3 retards tumor growth by PBRM1-deficient ccRCC cells. Thus after VHL inactivation, HIF induces ISGF3, which is reversed by the loss of secondary tumor suppressors, suggesting that this is a key negative feedback loop in ccRCC.
Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP)
Hsiao, Edward C. , Rocco, Maja Di , Cali, Amanda, Zasloff, Michael , Mukaddam, Mona Al , Pignolo, Robert J. , Grunwald, Zvi, Netelenbos, Coen , Keen, Richard , Brown, Matthew A. , Cunto, Carmen De , Delai, Patricia , Haga, Nobuhiko , Morhart, Rolf, Scott, Christiaan , Zhang, Keqin , Diecidue, Robert J. , Friedman, Clive, Kaplan, Frederick S. , Eekhoff, Elisabeth M. W. , Hsiao, Edward C , Baujat, Geneviève , Cho, Tae‐Joon , Brown, Matthew , Kaplan, Frederick S

Mayo Clinic

British Journal of Clinical Pharmacology | October 5, 2018 | Volume: 85 | Issue: 6 | Pages: 1199-1207

10.1111/bcp.13777 | PMID 30281842 Get It

Clinical trials for orphan diseases are critical for developing effective therapies. One such condition, fibrodysplasia ossificans progressiva (FOP; MIM#135100), is characterized by progressive heterotopic ossification (HO) that leads to severe disability. Individuals with FOP are extremely sensitive to even minor traumatic events. There has been substantial recent interest in clinical trials for novel and urgently‐needed treatments for FOP. The International Clinical Council on FOP (ICC) was established in 2016 to provide consolidated and coordinated advice on the best practices for clinical care and clinical research for individuals who suffer from FOP. The Clinical Trials Committee of the ICC developed a focused list of key considerations that encompass the specific and unique needs of the FOP community – considerations that are endorsed by the entire ICC. These considerations complement established protocols for developing and executing robust clinical trials by providing a foundation for helping to ensure the safety of subjects with FOP in clinical research trials.
Metabolomic Analyses Reveal Extensive Progenitor Cell Deficiencies in a Mouse Model of Duchenne Muscular Dystrophy
Joseph, Josiane , Cho, Dong Seong , Doles, Jason D. , Doles, Jason D

Mayo Clinic

Metabolites | October 4, 2018 | Volume: 8 | Issue: 4 | Pages: 61

10.3390/metabo8040061 | PMID 30282911 Get It

Duchenne muscular dystrophy (DMD) is a musculoskeletal disorder that causes severe morbidity and reduced lifespan. Individuals with DMD have an X-linked mutation that impairs their ability to produce functional dystrophin protein in muscle. No cure exists for this disease and the few therapies that are available do not dramatically delay disease progression. Thus, there is a need to better understand the mechanisms underlying DMD which may ultimately lead to improved treatment options. The muscular dystrophy (MDX) mouse model is frequently used to explore DMD disease traits. Though some studies of metabolism in dystrophic mice exist, few have characterized metabolic profiles of supporting cells in the diseased environment. Using nontargeted metabolomics we characterized metabolic alterations in muscle satellite cells (SCs) and serum of MDX mice. Additionally, live-cell imaging revealed MDX-derived adipose progenitor cell (APC) defects. Finally, metabolomic studies revealed a striking elevation of acylcarnitines in MDX APCs, which we show can inhibit APC proliferation. Together, these studies highlight widespread metabolic alterations in multiple progenitor cell types and serum from MDX mice and implicate dystrophy-associated metabolite imbalances in APCs as a potential contributor to adipose tissue disequilibrium in DMD.